ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 61 | 73 | +12 |
| Shares | 30.4M | 50.2M | +19.7M (+64.9%) |
| Value | $160.4M | $427.9M | +$267.5M (+166.8%) |
New holders (25)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (13)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Nantahala Capital Management, LLC | 1,249,863 | $6.60M |
| Prosight Management, LP | 196,257 | $1.04M |
| Ergoteles LLC | 74,544 | $394.0K |
| Price T Rowe Associates Inc | 26,500 | $140.0K |
| State of Wisconsin Investment Board | 24,200 | $128.0K |
| Occudo Quantitative Strategies LP | 15,057 | $80.0K |
| New York Life Investments Alternatives | 13,793 | $73.0K |
| Quattro Financial Advisors LLC | 12,869 | $68.0K |
| Two Sigma Securities, LLC | 12,740 | $67.0K |
| Schonfeld Strategic Advisors LLC | 11,600 | $62.0K |
| Federated Hermes, Inc. | 2,220 | $12.0K |
| BNP Paribas Arbitrage, SA | 456 | $2.41K |
| UBS Group AG | 12 | $0 |